Claims
- 1. A compound having the formula ##STR195## including all stereoisomers thereof, wherein m is 1, 2 or 3;
- n is 0, 1, 2, 3 or 4;
- Z is --(CH.sub.2).sub.2 --, --CH.dbd.CH-- or ##STR196## wherein Y is O, a single bond or vinyl (--CH.dbd.CH--), with the provisos that when n is 0, if Z is ##STR197## then Y cannot be O; and when Z is --CH.dbd.CH--, n is 1, 2, 3 or 4; and when Y=vinyl, n=0;
- R is CO.sub.2 H, CO.sub.2 Alkali metal, CO.sub.2 lower alkyl, CH.sub.2 OH, CONHSO.sub.2 R.sup.3, CONHR.sup.3a or --CH.sub.2 -5-tetrazolyl, with the proviso that when R is --CH.sub.2 -5-tetrazolyl, and Z is other than --(CH.sub.2).sub.2 --, n is 1, 2, 3 or 4;
- X is O, S or NH;
- .sup.R.sup.1 is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, heteroaryl or heteroarylalkyl, or an amide ##STR198## wherein T is 1 to 12 and Ra is lower alkyl, aryl, cycloalkyl or cycloalkylalkyl);
- R.sup.2 is hydrogen, lower alkyl, aryl, or aralkyl; or
- R.sup.1 and R.sup.2 together with the N to which they are linked form a 5- to 8-membered ring which contains only the single N heteroatom; and
- R.sup.3 is lower alkyl, aryl or aralkyl; and
- R.sup.3a is hydrogen, lower alkyl, aryl or aralkyl;
- wherein the term "aryl" by itself or as part of another group refers to a monocyclic or bicyclic aromatic group containing from 6 to 10 carbons in the ring portion, which is unsubstituted or substituted with 1 or 2 substitutents which are lower alkyl, trifluoromethyl, halogen, lower alkoxy, arylalkoxy, hydroxy, alkylthio, alkylsulfinyl, alkylsulfonyl, arylthio, arylsulfinyl and/or arylsulfonyl;
- the term "cycloalkyl" by itself or as part of another group refers to a saturated cyclic hydrocarbon group containing 3 to 12 carbons, which is unsubstituted or substituted with halogen, lower alkyl, alkoxy and/or hydroxy;
- the term "cycloheteroalkyl" by itself or as part of another group refers to a 5-, 6- or 7-membered saturated ring which includes 1 or 2 heteroatoms which are nitrogen, oxygen and/or sulfur;
- the term "heteroaryl" by itself or as part of another group refers to a 5- or 6-membered aromatic ring which includes 1 or 2 heteroatoms which are nitrogen, oxygen or sulfur,
- the term "lower alkyl" or "alkyl" by itself or as part of another group refers to a straight or branched chain radical of up to 18 carbons which is unsubstituted or substituted with 1, 2 or 3 halogen, aryl, alkyl-aryl, haloaryl, cycloalkyl, alkylcycloalkyl, hydroxy or carboxy substituents;
- the term "lower alkenyl" or "alkenyl" by itself or as part of another group refers to a carbon chain of up to 16 carbons containing one double bond and which is unsubstituted or substituted with a halogen substituent; and
- the term "lower alkynyl" or "alkynyl" by itself or as part of another group refers to a carbon chain of up to 16 carbons containing one triple bond.
- 2. The compound as defined in claim 1 having the formula ##STR199##
- 3. The compound as defined in claim 2 having the formula ##STR200##
- 4. The compound as defined in claim 2 where m=1 and n=2.
- 5. The compound as defined in claim 2 having the formula ##STR201##
- 6. The compound as defined in claim 2 having the formula ##STR202##
- 7. The compound as defined in claim 2 wherein R is CO.sub.2 H, CONHSO.sub.2 R.sup.3 or --CH.sub.2 -5-tetrazolyl.
- 8. The compound as defined in claim 3 having the formula ##STR203##
- 9. The compound as defined in claim 1 wherein Z is ##STR204##
- 10. The compound as defined in claim 1 wherein Z is ##STR205##
- 11. The compound as defined in claim 1 wherein Z is ##STR206##
- 12. The compound as defined in claim 1 wherein Z is --(CH.sub.2).sub.2 -- or --CH.dbd.CH--.
- 13. The compound as defined in claim 2 having the name [1S-(.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[4-[(4-cyclohexylbutyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[4-[[[4-chlorophenyl)butyl]amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid or esters, or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-3-[[3-[4-[[(4-cyclohexylbutyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzeneacetic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-[2-[3-[4-[[(4-cyclohexylbutyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]phenoxy]acetic 839 acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[4-[[(1-piperidinylbutyl)amino]carbonyl]-2-oxazolyl]7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[4-[[[4-(4-hydroxyphenyl)butyl]amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[4-[(propylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof; [1S-(1.alpha. ,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[4-pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[4-[[(2-cyclohexylethyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof; 1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[4-[[(5,5-dimethylhexyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[4-[[[4-(4-methoxyphenyl)butyl]amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.(E),4.alpha.)]-2-[3-[4-[[(4-cyclohexyl-2-butenyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo [2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[4-[[4-cyclohexylidenebutyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[4-[(heptylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[2-[3-[4-[[(4-cyclohexylbutyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]ethyl]benzeneacetic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-3-[2-[3-[4-[[(4-cyclohexylbutyl)amino]ethyl]benzeneacetic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[2-[3-[4-[[(4-cyclohexylbutyl)amino] carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]ethyl]benzenepropanoic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[4-[(decylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[[(4-cyclohexylbutyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzeneacetic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[4-[(cyclohexylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[4-[[(1-methylethyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)] -2-[[3-[4-[[(8-cyclohexyloctyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-3-[2-[3-[4-[[(4-cyclohexylbutyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]ethyl]benzoic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-[2-[[3-[4-[[[4-(methylthiophenyl]butyl]amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-[2-[[3-[4-[[[4-[4-methylsulfonylphenyl]butyl]amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[4-[[(cyclohexylbutyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, ethyl ester; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)] -N-(4-(cyclohexylbutyl)-2-[2-[[2-(3-hydroxypropyl)phenyl]methyl]-7-oxabicyclo[2.2.1]hept-3-yl]-4-oxazolecarboxamide; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[4-[[(cyclohexylbutyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl-N-ethylbenzenepropanamide; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[[(4-cyclohexylbutyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanamide; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[4-[(phenylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[4-[(pentylmethylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[4-[(phenylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-[2-[[3-[4-[[amino[1,1'-biphenyl]-4-yl]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-4-[[(4-cyclohexylbutyl)methylamino]carbonyl]-2-oxazolyl]-7-oxabicyclo2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof; [1S-([1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-3-[4-[[(4-phenylbutyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[4-[[[4-(phenylmethoxy)phenyl]amino]carbonyl]-2-oxazolyl]-7-oxabicyclo2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-4-[[hydroxyphenyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[4-[[[4-(4-methoxyphenyl)butyl]amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-4-[[4-(4-chlorophenyl)butyl]amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[3-[4-[[(4-cyclohexylbutyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or its potassium or sodium salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[4-[(4-cyclohexylbutyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]-N-methylsulfonylbenzenepropanamide; [1S-[1.alpha.,2.alpha.,3.alpha.,4.alpha.]]-2-[[3-4-[(2-propynyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo2.2.1]hept-2-yl] methyl]benzenepropanoic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.(E),4.alpha.]]-2-[3-[4-[[(3-iodo-2-propenyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[4-[[4-(hydroxy-3-iodophenyl)butyl]amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[4-[(4-cyclohexylbutyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or its monopotassium salt; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-4-[(4-cyclohexylbutyl)amino]carbonyl]-2-oxazolyl-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or its monosodium salt; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[4-[(4-cyclohexylbutyl)amino]carbonyl]-1-H-imidazol-2-yl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[4-[[(1H-imidazol-1-yl)butylamino]carbonyl]-2-oxazolyl-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[4-[[[2-(4-chlorophenyl)ethyl]amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4)]-2-[[3-[4-[[(1,1,-dimethylethyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters of salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[4-[[(1,1-dimethylpropyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[4-[(octadecylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[4-[[[5-(cyclohexylamino)-5-oxopentyl]amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]-methyl]benzenepropanoic acid, or ester or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[4-[[(5-hydroxy-5-methylhexyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[3-[4-[[(5-carboxy-5-methylhexyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof; 1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[4-(aminocarbonyl)-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof; 1S-(1.alpha.,2.alpha.(E),3.alpha.,4.alpha.)]-3-2-[[3-[[(4-cyclohexylbutyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]phenyl]-2-propenoic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[4-[[[2-(4-fluorophenyl)-1,1-dimethylethylamino]carbonyl]2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof; 1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[4-[[4-(4-fluorophenyl)butyl]amino]carbonyl]-2-oxazolyl]-7-oxabicyclo2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[4-[[(2,2-dimethylbutyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[4-[(2,2-dimethylpropyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[4-[[(3,3-dimethylbutyl)amino]carbonyl-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[3-[4-[[[2-(4-fluorophenyl)ethyl]amino]carbonyl]-2-oxazolyl]-7-oxabicyclo-[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-4-[[(2-phenylethyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[4-[(6-heptynylamino]carbonyl]-2-oxazolyl]-7-oxabicyclo-[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof.
- 14. The compound as defined in claim 1 having the formula ##STR207##
- 15. The compound as defined in claim 14 where m=1 and n=2.
- 16. The compound as defined in claim 1 having the formula ##STR208##
- 17. The compound as defined in claim 1 having the formula ##STR209##
- 18. The compound as defined in claim 14 wherein R is CO.sub.2 H, CONHSO.sub.2 R.sup.3 or --CH.sub.2 -5-tetrazolyl.
- 19. The compound as defined in claim 14 having the formula ##STR210##
- 20. The compound as defined in claim 1 having the name [1S-[1.alpha.,2.alpha.(Z),3.alpha.,4.alpha.][-6-[3-[4[[(4-cyclohexylbutyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]-4-hexenoic acid, or esters or salts thereof; [1S-[1.alpha.,2.alpha.(Z),3.alpha.,4.alpha.]]-6-[3-[4-[[(4-cyclohexylbutyl)amino]carbonyl]-2-thiazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]-4-hexenoic acid, or esters or salts thereof; [1S[1.alpha.,2.alpha.(Z),3.alpha.,4.alpha.]]-6-[3-4-[[(4-cyclohexylbutyl)-methylamino]carbonyl]-2-oxazolyl]-7-oxabicyclo [2.2.1]hept-2-yl]-4-hexenoic acid, or esters or salts thereof; [1S-[1.alpha.,2.alpha.(Z),3.alpha.,4.alpha.]]-6-[3-[4-[(1-pyrrolidinyl)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept2-yl]-4-hexenoic acid, or esters or salts thereof; [1S-[1.alpha.,2.alpha.(Z),3.alpha.,4.alpha.]]-6-3-[4-(cyclohexylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]-4-hexenoic acid, or esters or salts thereof;. [1S-[1.alpha.,2.alpha.(Z),3.alpha.,4.alpha.]]-6-[3-4-[[(2-cyclohexylethyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept2-yl]-4-hexenoic acid, or esters or salts thereof; [1S-[1.alpha.,2.alpha.(Z),3.alpha.,4.alpha.]]-6-3-[4-[[2-(4-chlorophenyl)ethyl]amino]carbonyl]-2-oxazolyl]-7-oxabicyclo2.2.1]hept-2-yl]-4-hexenoic acid, or esters or salts thereof; [1S-[1.alpha.,2.alpha.(Z),3.alpha.,4.alpha.]]-6-[3-[4-[[(4-chlorophenyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]-4-hexenoic acid, or esters or salts thereof; [1S-[1.alpha.,2.alpha.(Z),3.alpha.,4.alpha.]]-6-[3-[4-[[[4-(4-chlorophenyl)butyl]amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]-4-hexenoic acid, or esters or salts thereof; [1S-[1.alpha.,2.alpha.(Z),3.alpha.,4.alpha.]]-6-[3-[4-[[(6-cyclohexylhexyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]-4-hexenoic acid, or esters or salts thereof; [1S-[1.alpha.,2.alpha.(Z),3.alpha.,4.alpha.]]-6-[3-[4-[[(6-cyclohexylhexyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept2-yl]-4-hexenoic acid, or esters or salts thereof; [1S-[1.alpha.,2.alpha.(Z),3.alpha.,4.alpha.]]-6-[3-[4-[[(4-cyclohexylbutyl)amino]carbonyl]-1H-imidazol-2-yl]-7-oxabicyclo[2.2.1]hept-2-yl]-4-hexenoic acid, or esters or salts thereof; [1S-[1.alpha.,2.alpha.(Z),3.alpha.,4.alpha.]]-6-[3-[4-[(propylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]-4-hexenoic acid, or esters or salts thereof; [1S-[1.alpha.,2.alpha.(Z),3.alpha.,4.alpha.]]-6-[3-[4-[[(4-butylphenyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo2.2.1]hept-2-yl]-4-hexenoic acid, or esters or salts thereof; [1S-[1.alpha.,2.alpha.(Z),3.alpha.,4.alpha.]]-6-[3-[4-[(2,3-dihydro-1H-indol-1-yl)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]-4-hexenoic acid, or esters or salts thereof; [1S-[1.alpha.,2.alpha.(Z),3.alpha.,4.alpha.]]-6-[3-[4-[[(4-cyclohexylbutyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]-N-(phenylsulfonyl)-4-hexenamide; 4-[[(4-cyclohexylbutyl)amino]carbonyl]-2-oxazolyl] -N-(methylsulfonyl)-7-oxabicyclo[2.2.1]-hept-2-yl]-4-hexenamide; [1S-[1.alpha.,2.alpha.(Z),3.alpha.,4.alpha.]]-7-[3-[4-[[(4-cyclohexylbutyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid, or esters or salts thereof; [1S-[1.alpha.,2.alpha.(Z),3.alpha.,4.alpha.]]-6-[3-[4-[[[4-(2-phenylethyl)-2-thiazolyl]amino]carbonyl]-2-oxazolyl]-7-oxabycyclo[2.2.1]hept-2-yl]-4-hexenoic acid, or esters or salts thereof; [1S-[1.alpha.,2.alpha.(E),3.alpha.,4.alpha.]]-6-[3-[4-[(7,7-dimethyloctyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]-4-hexenoic acid, or esters or salts thereof; 1S-1.alpha.,2.alpha.(E),3.alpha.,4.alpha.]]-6-[3-[4-[[(4-cyclohexylbutyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]-4-hexenoic acid, or esters or salts thereof; [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-3-[4-[[(4-(cyclohexylbutyl)amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]heptane-2-hexanoic acid, or esters or salts thereof.
- 21. A method of inhibiting platelet aggregation and bronchoconstriction, which comprises administering to the circulatory system of a mammalian host a therapeutically effective amount of a compound as defined in claim 1.
- 22. The method as defined in claim 21 wherein said compound is administered in an amount within the range of from about 0.1 to about 100 mg/kg.
- 23. A composition for inhibiting platelet aggregation and broncoconstriction comprising a therapeutically effective amount of a compound as defined in claim 1, and a pharmaceutically acceptable carrier therefor.
- 24. A method of inhibiting platelet aggregation which comprises administering to a mammalian host a therapeutically effective amount of a compound as defined in claim 1.
- 25. A method of inhibiting bronchoconstriction associated with asthma, which comprises administering to a mammalian host a therapeutically effective amount of a compound as defined in claim 1.
- 26. A method for improving post-ischemic myocardial function, which comprises administering to a mammalian host in need of such treatment a therapeutically effective amount of a compound as defined in claim 1.
- 27. A method for treating toxemia during pregnancy, which comprises administering to a mammalian host in need of such treatment a therapeutically effective amount of a compound as defined in claim 1.
- 28. A method for preventing or reducing venous thrombosis, which comprises administering to a mammalian host in need of such treatment a therapeutically effective amount of a compound as defined in claim 1.
- 29. A method for preventing or reducing platelet loss during extracorporeal circulation, which comprises administering to a mammalian host in need of such treatment a therapeutically effective amount of a compound as defined in claim 1.
- 30. A method for treating burn injuries and/or promoting wound healing, which comprises administering to a mammalian host in need of such treatment a therapeutically effective amount of a compound as defined in claim 1 in systemic or topical form.
- 31. A method for reducing post-ischemic myocardial injury, which comprises administering to a mammalian host in need of such treatment an effective amount of a compound as defined in claim 1 and a therapeutically effective amount of a thrombolytic agent within 6 hours of a myocardial infarction.
- 32. The method as defined in claim 31 wherein said thrombolytic is t-PA, streptokinase, urokinase, prourokinase or anisoylated plasminogenstreptokinase activator complex.
- 33. A compound having the structure ##STR211## wherein m is 1, 2 or 3; n is 0, 1, 2, 3 or 4; R.sub.z is CO.sub.2 H, CO.sub.2 alkyl or CO.sub.2 alkali metal; and
- R.sup.1 is lower alkyl, lower alkenyl, lower alkynyl, aralkyl, aryl, cycloalkyl, cycloalkylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, heteroaryl or heteroarylalkyl, or an amide ##STR212## wherein t is 1 to 12 and Ra is lower alkyl, aryl, cycloalkyl or cycloalkylalkyl);
- wherein the term "aryl" by itself or as part of another group refers to a monocyclic or bicyclic aromatic group containing from 6 to 10 carbons in the ring portion, which is unsubstituted or substituted with 1 or 2 substituents which are lower alkyl, trifluoromethyl, halogen, lower alkoxy, arylalkoxy, hydroxy, alkylthio, alkylsulfinyl, alkylsulfonyl, arylthio, arylsulfinyl and/or arylsulfonyl;
- the term "cycloalkyl" by itself or as part of another group refers to a saturated cyclic hydrocarbon group containing 3 to 12 carbons, which is unsubstituted or substituted with halogen, lower alkyl, alkoxy and/or hydroxy;
- the term "cycloheteroalkyl" by itself or as part of another group refers to a 5-, 6- or 7-membered saturated ring which includes 1 or 2 heteroatoms which are nitrogen, oxygen and/or sulfur;
- the term "heteroaryl" by itself or as part of another group refers to a 5- or 6-membered aromatic ring which includes 1 or 2 heteroatoms which are nitrogen, oxygen or sulfur,
- the term "lower alkyl" or "alkyl" by itself or as part of another group refers to a straight or branched chain radical of up to 18 carbons which is unsubstituted or substituted with 1, 2 or 3 halogen, aryl, alkyl-aryl, haloaryl, cycloalkyl, alkylcycloalkyl, hydroxy or carboxy substituents;
- the term "lower alkenyl" or "alkenyl" by itself or as part of another group refers to a carbon chain of up to 16 carbons containing one double bond and which is unsubstituted or substituted with a halogen substituent; and
- the term "lower alkynyl" or "alkynyl" by itself or as part of another group refers to a carbon chain of up to 16 carbons containing one triple bond.
- 34. The compound as defined in claim 33 having the structure ##STR213##
- 35. The compound as defined in claim 33 having the name [1S-([1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[4-[[(4-cyclohexylbutyl)oxy]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof.
- 36. A compound having the formula ##STR214## including all stereoisomers thereof, wherein m is 1, 2 or 3;
- n is 0, 1, 2, 3 or 4;
- Y is O, vinyl (--CH.alpha.CH--) or or a single bond, with the proviso that when n is O, Y is a single bond; and when Y=vinyl, n=0;
- R is CO.sub.2 H, CO.sub.2 alkali metal, CO.sub.2 lower alkyl,
- CONHSO.sub.2 R.sup.3 or --CH.sub.2 -5-tetrazolyl, with the proviso
- that when R is --CH.sub.2 -5-tetrazolyl, n is
- other than 0;
- X is O, S or NH;
- R.sup.1 is lower alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, cycloheteroalkyl or heteroaryl; and
- R.sup.2 is hydrogen, lower alkyl, aryl or aralkyl;
- wherein the term "aryl" by itself or as part of another group refers to a monocyclic or bicyclic aromatic group containing from 6 to 10 carbons in the ring portion, which is unsubstituted or substituted with 1 or 2 substituents which are lower alkyl, trifluoromethyl, halogen, lower alkoxy, arylalkoxy, hydroxy, alkylthio, alkylsulfinyl, alkylsulfonyl, arylthio, arylsulfinyl and/or arylsulfonyl;
- the term "cycloalkyl" by itself or as part of another group refers to saturated cyclic hydrocarbon groups containing 3 to 12 carbons, which is unsubstituted or substituted with halogen, lower alkyl, alkoxy and/or hydroxy;
- the term "cycloheteroalkyl" by itself or as part of another group refers to a 5-, 6- or 7-membered saturated ring which includes 1 or 2 heteroatoms which are nitrogen, oxygen and/or sulfur;
- the term "heteroaryl" by itself or as part of another group refers to a 5- or 6-membered aromatic ring which includes 1 to 2 heteroatoms which are nitrogen, oxygen or sulfur,
- the term "lower alkyl" or "alkyl" by itself or as part of another group refers to a straight or branched chain radical of up to 18 carbons which is unsubstituted or substituted with 1, 2 or 3 halogen, aryl, alkyl-aryl, haloaryl, cycloalkyl, alkylcycloalkyl, hydroxy or carboxy substituents;
- the term "lower alkenyl" or "alkenyl" by itself or as part of another group refers to a carbon chain of up to 16 carbons containing one double bond and which is unsubstituted or substituted with a halogen substituent; and
- the term "lower alkynyl" or "alkynyl" by itself or as part of another group refers to a carbon chain of up to 16 carbons containing one triple bond.
- 37. A compound having the formula ##STR215## including all stereoisomers thereof, wherein m is 1, 2 or 3;
- n is 1, 2, 3 or 4;
- R is CO.sub.2 H, CO.sub.2 alkali metal, CO.sub.2 lower alkyl,
- CONHSO.sub.2 R.sup.3 or --CH.sub.2 -5-tetrazolyl;
- X is O, S or NH;
- R.sup.1 is lower alkyl, aryl, aralkyl, cycloalkyl, or cycloalkylalkyl;
- R.sup.2 is hydrogen, lower alkyl, aryl, or aralkyl, or R.sup.1 and R.sup.2 together with the N to which they are linked form a 5- to 8- membered ring which contains only the single N heteroatom; and R.sup.3 is lower alkyl, aryl or aralkyl;
- wherein the term "aryl" by itself or as part of another group refers to monocyclic or bicyclic aromatic groups containing from 6 to 10 carbons in the ring portion, which is unsubstituted or substituted with 1 or 2 substituents which are lower alkyl, trifluoromethyl, halogen, lower alkoxy, arylalkoxy, hydroxy, alkylthio, alkylsulfinyl, alkylsulfonyl, arylthio, arylsulfinyl and/or arylsulfonyl;
- the term "cycloalkyl" by itself or as part of another group refers to saturated cyclic hydrocarbon groups containing 3 to 12 carbons, which is unsubstituted or substituted with halogen, lower alkyl, alkoxy and/or hydroxy; and
- the term "lower alkyl" or "alkyl" by itself or as part of another group refers to a straight or branched chain radicals of up to 18 carbons which is unsubstituted or substituted with 1, 2 or 3 halogen, aryl, alkyl-aryl, haloaryl, cycloalkyl, alkylcycloalkyl, hydroxy or carboxy substitutents.
- 38. A compound having the name [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[4-[[[2-(4-chlorophenyl)ethyl]amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof.
- 39. A compound having the name [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[4-(pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid or esters or salts thereof.
- 40. A compound having the structure ##STR216##
- 41. A compound having the name [1S-(1.alpha.,2.alpha.,3.alpha.,4.alpha.)]-2-[[3-[4-[[amino[1,1'-biphenyl[-4-yl]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid, or esters or salts thereof.
REFERENCE TO OTHER APPLICATIONS
The present application is a continuation-in-part of U.S. application Ser. No. 442,818 filed Nov. 28, 1989, which is a continuation-in-part of U.S. application Ser. No. 433,301 filed Nov. 8, 1989, which is a continuation of U.S. Ser. No. 288,826 filed Dec. 23, 1988, and is a continuation-in-part of U.S. application Ser. No. 334,070 filed Apr. 3, 1989.
US Referenced Citations (8)
Non-Patent Literature Citations (3)
Entry |
As Belo Bioorg Chem, 04.03.81-SU278256 (23.11.87) C07C-177 C07D-261/06. |
Chem Abs. SA Selects: Prostaglandins Issue 12, 1988 108:198903m. Kuz'mitskii, B. B. et al. |
CA Selects: Prostaglandins, Issue 12, 1988, 108:204363d, Lakhvich, F. A. et al. |
Continuations (1)
|
Number |
Date |
Country |
Parent |
288826 |
Dec 1988 |
|
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
442818 |
Nov 1989 |
|
Parent |
433301 |
Nov 1989 |
|